Evogene (EVGN) Payables (2012 - 2026)

Evogene has disclosed Payables across 15 years of filings, most recently posting $394000.0 for Q2 2026.

• In Q2 2026, Payables fell 29.26% year-over-year to $394000.0; the TTM figure through Jun 2026 stood at $394000.0 (down 29.26% YoY), while the FY2025 annual figure was $639000.0, down 47.96% from the prior year.
• Payables came in at $394000.0 for Q2 2026 at Evogene, down from $463000.0 in the prior quarter.
• In the past five years, Payables ranged from a high of $1.8 million in Q4 2023 to a low of $394000.0 in Q2 2026.
• Average Payables over 5 years is $966666.7, with a median of $1.0 million recorded in 2022.
• Year-over-year, Payables soared 72.3% in 2023 and plunged 61.85% in 2025.
• Over 5 years, Payables stood at $1.0 million in 2022, then soared by 72.3% to $1.8 million in 2023, then tumbled by 31.2% to $1.2 million in 2024, then tumbled by 47.96% to $639000.0 in 2025, then tumbled by 38.34% to $394000.0 in 2026.
• Per Business Quant data, the three most recent Payables figures were $394000.0 in Q2 2026, $463000.0 in Q1 2026, and $639000.0 in Q4 2025.